Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CStone Pharmaceuticals ( (HK:2616) ) just unveiled an update.
CStone Pharmaceuticals announced the approval of their Investigational New Drug application by the China National Medical Products Administration for Phase II clinical trials of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, for advanced solid tumors. This approval is expected to accelerate the clinical development of CS2009, which is currently enrolling patients in Australia and will soon expand to China and the United States, potentially strengthening CStone’s position in the biopharmaceutical industry and offering new therapeutic options for various cancers.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on developing therapies for oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. CStone’s pipeline includes promising candidates such as antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines, supported by a management team with comprehensive drug development experience.
Average Trading Volume: 22,471,424
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.1B
Find detailed analytics on 2616 stock on TipRanks’ Stock Analysis page.